← All trials
NCT04788407
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2020
- Primary completion
- Apr 30, 2022
- Completion date
- Apr 30, 2022
- First posted
- Mar 9, 2021
- Last posted
- Jul 2, 2021
- Enrollment
- 456
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Fundacion HuespedLead sponsor
- Government of ArgentinaCollaborator
- Fundacion HuespedReponsible party - principal investigator
- Fundacion HuespedOverall official - principal investigator
- Laboratorios Roemmers S.A.I.C.F.Collaborator
- Fundacion HuespedStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.